causal

Lax trial standards raise barriers for small entrants

By allowing studies without control arms, inadequate control arms, or surrogate endpoints like tumor shrinkage, the FDA creates a bar that is hard for small entrants to clear while making it easy to sustain lofty prices—producing a system that benefits large corporations and penalizes small entrepreneurs without guaranteeing the product works.

causalpending

Speaker

Vinay Prasad

Evidence Quote

“It's a system that I think benefits large corporations. It penalizes the small entrepreneur.”

Source

Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty— EconTalk
Created: 6/13/2026, 3:32:57 AM

Your notes

Loading notes...